BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26229972)

  • 1. Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.
    Hu P; Li Y; Sands MS; McCown T; Kafri T
    Mol Ther Methods Clin Dev; 2015; 2():15025. PubMed ID: 26229972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
    Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
    Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.
    Xu K; Ma H; McCown TJ; Verma IM; Kafri T
    Mol Ther; 2001 Jan; 3(1):97-104. PubMed ID: 11162316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient Expression of Green Fluorescent Protein in Integrase-Defective Lentiviral Vector-Transduced 293T Cell Line.
    Nordin F; Hamid ZA; Chan L; Farzaneh F; Hamid MK
    Methods Mol Biol; 2016; 1448():159-73. PubMed ID: 27317180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
    Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
    J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization.
    Bona R; Michelini Z; Mazzei C; Gallinaro A; Canitano A; Borghi M; Vescio MF; Di Virgilio A; Pirillo MF; Klotman ME; Negri D; Cara A
    Mol Ther Methods Clin Dev; 2021 Dec; 23():263-275. PubMed ID: 34729374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
    J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A packaging cell line for lentivirus vectors.
    Kafri T; van Praag H; Ouyang L; Gage FH; Verma IM
    J Virol; 1999 Jan; 73(1):576-84. PubMed ID: 9847362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors.
    Kuate S; Wagner R; Uberla K
    J Gene Med; 2002; 4(4):347-55. PubMed ID: 12124977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines.
    Stewart HJ; Leroux-Carlucci MA; Sion CJ; Mitrophanous KA; Radcliffe PA
    Gene Ther; 2009 Jun; 16(6):805-14. PubMed ID: 19262613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Integration-defective HIV-1 and EIAV Vectors In Vitro and In Vivo.
    Ellis S; Fong-Wong L; Iqball S; Thoree V; Mitrophanous KA; Binley K
    Mol Ther Nucleic Acids; 2012 Dec; 1(12):e60. PubMed ID: 23232328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.
    Bell AJ; Fegen D; Ward M; Bank A
    Exp Biol Med (Maywood); 2010 Oct; 235(10):1269-76. PubMed ID: 20876083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells.
    Humbert O; Gisch DW; Wohlfahrt ME; Adams AB; Greenberg PD; Schmitt TM; Trobridge GD; Kiem HP
    Mol Ther; 2016 Aug; 24(7):1237-46. PubMed ID: 27058824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Optimized Protocol for Packaging Pseudotyped Integrase Defective Lentivirus.
    Sengupta R; Mukherjee C; Sarkar N; Sun Z; Lesnik J; Huang J; Lu B
    Biol Proced Online; 2016; 18():14. PubMed ID: 27403084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.
    Gallinaro A; Borghi M; Bona R; Grasso F; Calzoletti L; Palladino L; Cecchetti S; Vescio MF; Macchia D; Morante V; Canitano A; Temperton N; Castrucci MR; Salvatore M; Michelini Z; Cara A; Negri D
    Front Immunol; 2018; 9():171. PubMed ID: 29459873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein.
    Yang Y; Vanin EF; Whitt MA; Fornerod M; Zwart R; Schneiderman RD; Grosveld G; Nienhuis AW
    Hum Gene Ther; 1995 Sep; 6(9):1203-13. PubMed ID: 8527479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
    Persons DA; Mehaffey MG; Kaleko M; Nienhuis AW; Vanin EF
    Blood Cells Mol Dis; 1998 Jun; 24(2):167-82. PubMed ID: 9642098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the titer and infectivity of lentiviral vectors.
    Logan AC; Nightingale SJ; Haas DL; Cho GJ; Pepper KA; Kohn DB
    Hum Gene Ther; 2004 Oct; 15(10):976-88. PubMed ID: 15585113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
    Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
    Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stable system for the high-titer production of multiply attenuated lentiviral vectors.
    Klages N; Zufferey R; Trono D
    Mol Ther; 2000 Aug; 2(2):170-6. PubMed ID: 10947945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.